Loomis, Sayles & Company’s Xenon Pharmaceuticals XENE Stock Holding History

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$32.8M	Sell	564,897 -47,135	-8%	-$2.17M	0.04%	153
2025 Q4	$27.4M	Sell	612,032 -28,594	-4%	-$1.2M	0.03%	188
2025 Q3	$25.7M	Sell	640,626 -16,539	-3%	-$583K	0.03%	201
2025 Q2	$20.6M	Sell	657,165 -15,846	-2%	-$517K	0.03%	239
2025 Q1	$22.6M	Sell	673,011 -14,134	-2%	-$537K	0.03%	225
2024 Q4	$26.9M	Sell	687,145 -20,077	-3%	-$830K	0.03%	213
2024 Q3	$27.8M	Buy	707,222 +46,964	+7%	+$1.89M	0.04%	211
2024 Q2	$25.7M	Sell	660,258 -26,252	-4%	-$1.05M	0.04%	216
2024 Q1	$29.6M	Sell	686,510 -21,785	-3%	-$1M	0.04%	202
2023 Q4	$32.6M	Sell	708,295 -22,421	-3%	-$792K	0.05%	182
2023 Q3	$25M	Sell	730,716 -22,810	-3%	-$853K	0.04%	214
2023 Q2	$29M	Sell	753,526 -7,041	-0.9%	-$280K	0.05%	196
2023 Q1	$27.2M	Buy	760,567 +83,402	+12%	+$3.08M	0.05%	194
2022 Q4	$26.7M	Buy	+677,165	New	+$24.7M	0.05%	189